Tesamorelin
Tesamorelin API
Tesamorelin is a synthetic peptide drug, the full name is ThGRF(1-44)NH₂, which is a growth hormone releasing hormone (GHRH) analog. It stimulates the anterior pituitary to secrete growth hormone (GH) by simulating the action of endogenous GHRH, thereby indirectly increasing the level of insulin-like growth factor 1 (IGF-1), bringing a series of benefits in metabolism and tissue repair.
Currently, Tesamorelin has been approved by the FDA for the treatment of HIV-related lipodystrophy, especially for reducing abdominal visceral fat accumulation (visceral adipose tissue, VAT). It has also been widely studied for **anti-aging, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD/NASH)** and other fields, showing broad application prospects.
Mechanism of action
Tesamorelin is a 44-amino acid peptide with a structure highly similar to natural GHRH. Its mechanism of action is:
Activate GHRH receptor (GHRHR) to stimulate the anterior pituitary to release GH.
After GH is elevated, it acts on the liver and surrounding tissues to increase IGF-1 synthesis.
GH and IGF-1 jointly participate in fat metabolism, protein synthesis, cell repair and bone density maintenance.
It mainly acts on visceral fat decomposition (fat mobilization) and has little effect on subcutaneous fat.
Compared with direct exogenous injection of GH, Tesamorelin promotes GH secretion through endogenous mechanisms, which is closer to the physiological rhythm and avoids adverse reactions caused by excessive GH, such as water retention and insulin resistance.
Research and clinical efficacy
The efficacy of Tesamorelin has been verified through multiple clinical trials, especially in the following areas:
1. HIV-related lipodystrophy (FDA-approved indications)
Tesamorelin can significantly reduce abdominal VAT (an average decrease of 15-20%);
Increase IGF-1 levels and improve the body's metabolic state;
Improve body shape and reduce the psychological burden associated with fat redistribution;
Does not significantly affect the subcutaneous fat layer, bone density or muscle mass.
2. Non-alcoholic steatohepatitis (NASH) and liver fibrosis
Clinical trials have shown that Tesamorelin can reduce liver fat content (MRI-PDFF imaging);
It is expected to improve hepatocyte insulin sensitivity;
It is particularly effective for patients with HIV and NAFLD, and has potential broad-spectrum metabolic protection.
3. Metabolic syndrome and insulin resistance
Tesamorelin significantly reduces triglyceride levels and abdominal obesity;
Improves HOMA-IR index and assists in improving insulin resistance;
Studies have shown that it can enhance muscle protein synthesis capacity, which is beneficial to the elderly or chronic disease recovery.
API production and quality control
The Tesamorelin API provided by our Gentolex Group adopts advanced solid phase peptide synthesis technology (SPPS) and is produced under GMP environment. It has the following characteristics:
Purity ≥99% (HPLC)
No endotoxin, heavy metal, residual solvent detection qualified
Amino acid sequence and structure confirmation by LC-MS/NMR
Provide gram-level to kilogram-level customized production
